TRAIL/TNFSF10 蛋白, Human (HEK293, His-Flag)

TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways^[1][2]. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell^[1]. TRAIL/TNFSF10 Protein, Human (HEK293, His-Flag) is a recombinant human TRAIL (G118-G281) with N-terminal His and Flag tag, which is expressed in HEK293.

TRAIL 蛋白（TNFSF10）是 TNF 超家族的成员，是一种 II 型跨膜蛋白。TRAIL蛋白在多种组织中表达，特别是在脾、肺和前列腺中。TRAIL蛋白主要表达于免疫细胞表面，如细胞毒性T细胞和自然杀伤（NK）细胞。NK 和 T 细胞上的 TRAIL 蛋白对于控制病毒感染和肿瘤免疫监视至关重要^[1][2]。
人类 TRAIL 由细胞质结构域 (M1 -V17)、螺旋结构域(L18-F38)和胞外结构域(T39-G281)。人类 TRAIL 蛋白与小鼠和大鼠的共同氨基酸一致性< 70%。小鼠 TRAIL 蛋白与大鼠有 86.94% 的共同氨基酸同一性。
TRAIL蛋白主要与两种激动性TRAIL受体（TRAIL-R1和TRAIL-R2）相互作用，诱导肿瘤或感染细胞凋亡。TRAIL 蛋白还与 DR4、DR5 和 OPG 结合。当与 DR4 或 DR5 结合时，TRAIL 蛋白可以招募 FADD，并进一步招募并激活 caspase-8。此外，TRAIL 还可能通过激活促炎通路（如 NF-κB、PI3K/Akt 和 MAPK 通路）来触发非凋亡信号传导^[1][2]。
TRAIL 以不依赖 p53 的方式诱导肿瘤细胞凋亡。基于 TRAIL 的疗法具有很高的抗肿瘤潜力^[3]。

TRAIL (human, 1 ng/mL-1 μg/mL, 24 h) reduces cell viability of HepG2 cells^[4].
TRAIL (human, 1-1 ng, 24 h) induces pathognomic features of asthma and stimulates the production of CCL2 in primary human bronchial epithelium cells^[5].

Human

HEK293

N-His;N-Flag

P50591 (G118-G281)

8743  [NCBI]

55-65 kDa

Greater than 95% as determined by Tris-Bis PAGE.

<1 EU/μg, determined by LAL method.

• [1]. Cardoso Alves L, et al. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J. 2021 Oct;288(19):5530-5554.  [Content Brief]

  [2]. Zhong HH, et al. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385.  [Content Brief]

  [3]. Snajdauf M, et al. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021 Mar 10;8:628332.  [Content Brief]

  [4]. Ganten TM, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006 Apr 15;12(8):2640-6.  [Content Brief]

  [5]. Weckmann M, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med. 2007 Nov;13(11):1308-15.  [Content Brief]